Raj Chovatiya, MD, PhD, is Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Chovatiya received his MD and PhD in immunology from Yale University. He completed his internship at Yale followed by residency and postdoctoral research fellowship at Northwestern, where he also served as Chief Resident. Dr. Chovatiya leads the Center for Eczema and Itch at Northwestern, and his clinical focus includes atopic dermatitis, eczema, chronic itch, and other chronic inflammatory skin disorders such as seborrheic dermatitis, psoriasis, urticaria, hidradenitis, and vitiligo. Dr. Chovatiya’s research focus includes the intersection of cutaneous immunology and inflammatory disease. He has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, and improving care across diverse skin types. He has published numerous abstracts and manuscripts and has been recognized for his contributions as a speaker, researcher, and leader at national and international conferences.
Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
December 23rd 2022In part 5 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.
Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
December 22nd 2022In part 4 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.
Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
December 21st 2022In part 3 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.
Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
December 20th 2022In part 2 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.
Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
December 19th 2022In part 1 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.
Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management
December 13th 2022Raj Chovatiya, M.D., Ph.D. and Neal Bhatia, MD comment on the importance of assessing a treatment’s available clinical trial data, ability to control disease severity, and QoL impacts when assessing atopic dermatitis treatment options.